On June 25, Sino Biopharmaceutical fell 3.17% in regular trading, trading at HK$4.29/share, with turnover of HK$58.17 million.

On the news front, the pharmaceutical sector experienced another broad-based pullback, with peers CSPC Pharmaceutical down 2.5%, Asymchem down 2.04%, and Hutchmed down 1.48%. The stock's short-selling ratio remains elevated at 24.21%, reflecting strong bearish positioning. Morgan Stanley previously lowered its target price from HK$8.3 to HK$7.8 while maintaining an Overweight rating.

Despite the company announcing a share repurchase plan of up to HK$2 billion over the next 12 months and recent dual-pipeline catalysts including NMPA approval of Peceleganan Spray for burn wound infections, the stock resumed its decline after a brief two-day rebound. The 52-week low has been tested near HK$4.37, underscoring significant market divergence between fundamental developments and price action amid continued sector-wide valuation compression.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)